Search results
297 Results for 'Biotechnology'
- Technologies (39)
- Collaborations (2)
- Team (0)
- News (206)
- Pages (0)
- Multimedia (50)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 39
-
COPDx: Rapid diagnostic to triage acute exacerbations
A point-of-care test based on new biomarkers to rapidly identify COPD patients who are high risk of acute exacerbations (AEs), determine the cause, and guide treatment. -
GC Therapeutics: Changing the Future of Cell Therapies
GC Therapeutics (GCTx) is applying their stem cell-engineering TFome platform to overcome barriers in the development and manufacturing of cell therapies to improve patient access across a broad range of disease areas. -
Instrument-Free Molecular Diagnostics
A synthetic biology-based molecular diagnostics platform that enables the creation of low-cost, highly accurate tests for non-clinical settings. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
NodeTX: Growing Lymph Nodes to Treat Cancer
NodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors. -
Crisscross Nanoseed Detection: Nanotechnology-Powered Infectious Disease Diagnostics
This nanotech-based diagnostic platform uses a unique nucleation mechanism that assembles a DNA "nanoseed" in the presence of a pathogen-derived biomarker that then is amplified within 15 minutes to create a signal for easy detection. It is highly robust, and cost-effective, and can be adapted to detect a variety of biomarkers.
Collaborations 2
-
Brigham-Wyss DxA
The Wyss DxA's clinical partners from Brigham and Women’s Hospital identify the most pressing unmet diagnostic needs, provide access to high-quality patient samples for our Biomarker Discovery Laboratory (BDL) and Brigham-Wyss DxA collaborators, and provide invaluable feedback and guidance on the engineering and validation of cost-effective, sensitive, and specific diagnostic tests. -
Wyss Brain Targeting Program
Advancing brain delivery approaches that enable more safe and effective brain-targeted therapeutics.
News 206
Multimedia 50
-
Video/Animation20-ish Questions with David Walt20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David Walt, a Core Faculty member of the Wyss Institute as well as the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard Medical School, a Professor of... -
Video/Animation20-ish Questions with Samir Mitragotri20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows Samir Mitragotri, a Core Faculty member of the Wyss Institute as well as a Professor of Bioengineering and Biologically Inspired Engineering at the Harvard John A. Paulson School... -
Video/AnimationESCAPE BioengineeringA research team at the Wyss Institute and Boston University has developed ESCAPE, the first method that enables the engineering of tissues across multiple length scales, ranging from the diameter of a cell to the cm scale of a heart valve. Credit: Wyss Institute at Harvard University -
Video/AnimationWhat is the future of Engineering with Bioengineering Pioneer Donald E Ingber – Museum of ScienceIs biological inspiration the key to the future of engineering? Bioethicist Insoo Hyun sits down with Donald E. Ingber, Founding Director of the Wyss Institute for Biologically Inspired Engineering and Professor of Bioengineering at Harvard’s School of Engineering & Applied Sciences. Together they explore the profound impact of Nature on engineering beyond the realms of... -
Audio/PodcastReimagining Infertility – An Interview with Christian KrammeChristian Kramme imagines a world where all people can have a child on their own time frame. Such “reproductive autonomy” is not the case today – infertility is a growing problem worldwide, and existing treatments like IVF are incredibly taxing on women’s bodies and too expensive for most of the global population to access. Listen... -
Video/AnimationFeCILL: Reimagining How We Treat the Sickest PatientsOpportunistic fungal infections usually only affect patients whose immune systems are compromised, but when they do, they are often deadly – the mortality rate for these infections can be as high as 25%. Existing antifungal treatments have high levels of toxicity, and can harm the patient more than they help. Researchers at the Wyss Institute...